ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS ADXN 深 滬
已收盤 08-15 16:00:00 美东时间
7.94
+0.420
+5.59%
華盛通- 最 高8.01
- 今 開7.90
- 成交量 943股
- 最 低 7.90
- 昨 收 7.52
- 總市值 848.87万
- 52周最高 13.27
- 市盈率 靜 1.38
- 換手率 0.09%
- 52周最低 6.51
- 委 比 90.91%
- 總股本 106.91万
- 歷史最高 750.40
- 量 比 0.61
- 振 幅 1.46%
- 歷史最低 0.00
- 每 手 1
- 風險率 1.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development
Addex Therapeutics (NASDAQ:ADXN) has led a CHF 2 million investment in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. The funding will enable ...
06-30 15:32
Earnings Scheduled For June 19, 2025
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is likely to report earni...
06-19 16:32
Addex Therapeutics Q1 EPS $(1.33) Up From $(1.37) YoY, Sales $78.93K Down From $268.83K YoY
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.33) per share. This is a 2.92 percent increase over losses of $(1.37) per share from the same period last year. The company reported $78.93 thousand in
06-19 14:39
Addex Therapeutics shares are trading higher after the company reported its preclinical results for GABAB PAM.
Addex Therapeutics shares are trading higher after the company reported its pre...
06-07 03:11
Addex Therapeutics Advances GABAB PAM Programs with Indivior Partnership
The latest update is out from Addex Therapeutics ( ($CH:ADXN) ). Addex Therapeu...
05-12 13:37
Addex Therapeutics reports FY results
Addex Therapeutics press release (NASDAQ:ADXN): FY GAAP EPS of CHF 0.04. Income CHF 410K. More on Addex Therapeutics J&J hands epilepsy candidate to Addex ending decades-long partnership Seeking Alpha...
04-25 16:10
Addex Therapeutics to Announce Full-Year 2024 Financial Results
Addex Therapeutics ( ($CH:ADXN) ) just unveiled an update. Addex Therapeutics a...
04-24 13:40
J&J hands epilepsy candidate to Addex ending decades-long partnership
Swiss biopharma Addex Therapeutics (NASDAQ:ADXN) announced Thursday that Johnson & Johnson (NYSE:JNJ) has returned all development and commercialization rights linked to its epilepsy candidate ADX7114...
04-18 01:30
Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M
Key Half Year and Q2 2024 Financial Data:CHF' thousandsQ2 24Q2 23*ChangeH1 24H1 23*ChangeIncome115632(517)3501,134(784)R&D expenses(339)(291)(48)(584)(547)(37)G&A
2024-09-30 14:49
Addex Therapeutics reports H1 results
Addex Therapeutics press release (NASDAQ:ADXN): H1 net gain of CHF 9.8 million. The cash position of the Group amounted to CHF 3.8 million as of June 30, 2024. More on Addex Therapeutics Addex stock r...
2024-09-19 22:35
